All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

tafluprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prostaglandins	4229	209860-87-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tafluprost tafluprost ophthalmic solution zioptan taflotan tapros	a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow Molecular weight: 452.54 Formula: C25H34F2O5 CLOGP: 4.26 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 75.99 ALOGS: -4.93 ROTB: 13 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 10, 2012	FDA	OAK PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	192.53	35.18	48	779	20244	50584053
Eye irritation	149.74	35.18	38	789	17102	50587195
Eye pain	117.44	35.18	35	792	28414	50575883
Eye pruritus	100.55	35.18	26	801	12508	50591789
Eye swelling	50.55	35.18	17	810	20127	50584170

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	79.20	56.25	19	343	9108	29565057
Eye irritation	60.09	56.25	14	348	5884	29568281

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	125.28	36.09	34	889	22530	64475279
Eye pain	72.06	36.09	24	899	31601	64466208
Eye irritation	61.12	36.09	18	905	15838	64481971
Eye pruritus	42.82	36.09	13	910	12646	64485163
Pemphigoid	42.50	36.09	13	910	12973	64484836
Atrioventricular block second degree	41.74	36.09	11	912	6443	64491366

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01EE05	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
FDA CS	M0017805	Prostaglandins
FDA MoA	N0000000106	Prostaglandin Receptor Agonists
FDA PE	N0000009526	Increased Prostaglandin Activity
FDA EPC	N0000175454	Prostaglandin Analog
CHEBI has role	CHEBI:66900	prostaglandin receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Open-angle glaucoma	indication	84494001	DOID:1067

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.0015%	ZIOPTAN	THEA PHARMA	N202514	Feb. 10, 2012	RX	SOLUTION/DROPS	OPHTHALMIC	5886035	Dec. 18, 2022	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
0.0015%	ZIOPTAN	THEA PHARMA	N202514	Feb. 10, 2012	RX	SOLUTION/DROPS	OPHTHALMIC	10864159	May 28, 2029	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prostaglandin F2-alpha receptor	GPCR	P43088	PF2R_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
4031331	VUID
N0000184322	NUI
D06274	KEGG_DRUG
4031331	VANDF
C1451502	UMLSCUI
CHEBI:66899	CHEBI
CHEMBL1963683	ChEMBL_ID
DB08819	DRUGBANK_ID
C485333	MESH_SUPPLEMENTAL_RECORD_UI
7451	IUPHAR_LIGAND_ID
8374	INN_ID
1O6WQ6T7G3	UNII
9868491	PUBCHEM_CID
1244607	RXNORM
187543	MMSL
26696	MMSL
013244	NDDF
699181001	SNOMEDCT_US
704470009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ZIOPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	17478-609	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	NDA	25 sections
ZIOPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	17478-609	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	NDA	25 sections